Skip to main content

Urinary Diversion–Specific Pharmacotherapy

Pharmacotherapy specific to patients with urinary diversion (ileal conduit, orthotopic neobladder, continent cutaneous reservoir, augmentation cystoplasty) — acid-base management, vitamin B12 supplementation, and mucus-production control. The shared theme: bowel-in-the-urinary-tract creates predictable physiologic perturbations that require lifelong surveillance and targeted pharmacologic management.

For diversion technique itself see Urinary Diversion Principles and the named-procedure pages.

  • Mucus ManagementSaline as the mainstay; NAC in-vitro-vs-clinical mismatch (N'Dow 2001 RCT negative despite robust mucolytic effect in vitro); octreotide 75% reduction data; urea rescue; explicit de-prescribe rule for ranitidine and aspirin (legacy, no benefit).
  • Vitamin B12 SupplementationAnatomic-risk-by-segment table (Kock 80% Schilling+ vs ileal neobladder 0%); NCCN v1.2026 annual monitoring; oral B12 1–2 mg/day via passive diffusion as the emerging standard (replaces parenteral injection in most patients); andrology cross-reference (Rastegar Panah testosterone).
  • Urinary Acidifiers & AlkalinizersMüller 2020 continence-acidosis paradox (45% → 87% continent with deliberate acidemia management); KDIGO HCO₃⁻ < 18 trigger; NH₄Cl loading test vs F+F test; ascorbic acid does not reliably acidify urine + Ferraro 2016 male stone-risk 43% HR caveat.